Greg Hamilton

Greg Hamilton currently serves as the CEO of Accellix since September 2024 and as a Board Member at io9 Inc. since August 2023, focusing on Biotech Artificial Intelligence. Hamilton's extensive experience includes previous roles as Board Member at EraCal Therapeutics from December 2021 to April 2024 and CEO of Epigenomics AG from July 2016 to July 2023. Other significant positions include Chief Executive Officer at AltheaDx (May 2013 - April 2016), President and CEO at RGTN Inc. (February 2012 - May 2013), and Chief Operating Officer and Chief Financial Officer at Enigma Diagnostics (October 2009 - January 2012). Hamilton also held the role of Vice President of Operations, Planning & Analysis at Hologic (July 2008 - November 2009) and Vice President Finance and Operations at Third Wave Technologies (February 2005 - July 2008). Early career experience includes Vice President and Chief Financial Officer at Leo Burnett (2002 - 2004). Academic credentials include an MBA from The University of Chicago Booth School of Business and a BS in Finance from Purdue University Daniels School of Business.